在澳大利亚一只狗中成功治疗肺性梅利欧症
J R Fletcher1, E K Cook1, G L Birnie1
1Animal Referral Hospital, Brisbane, Queensland, 4073, Australia.
Australian veterinary journal
|February 11, 2026
概括
本案例研究详细介绍了西伯利亚哈斯基 (Siberian Husky) 患有罕见的细菌感染 - - 肺结核病的成功治疗方法. 经过手术和延长抗微生物治疗后,这只狗康复了,突出了这种犬病的新型治疗方法.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 传染性疾病 传染性疾病
- 肺部病理学 肺部病理学
背景情况:
- 由于Burkholderia pseudomallei引起的犬性症是一种严重的细菌感染.
- 肺部干扰在狗中存在重大诊断和治疗挑战.
- 洪水事件可能会增加暴露于环境病原体的风险,如B. pseudomallei.
研究的目的:
- 报告首次成功治疗来自以前不被认为是特有地区的狗肺性梅略症的病例.
- 描述复杂的犬肉结核病病例的临床表现,诊断过程和治疗管理.
- 强调及时诊断和多模式治疗的重要性,包括手术和向抗菌疗法.
主要方法:
- 在洪水事件后,西伯利亚哈斯基患有呼吸困难和发烧症的临床病例呈现.
- 诊断工作包括胸部成像 (CT扫描),血液检查和微生物培养.
- 治疗包括支持性护理,广泛的抗微生物药物,手术切除骨,以及延长的抗微生物治疗.
- 组织病理学检查证实了丧尸性支气管间歇性肺炎.
主要成果:
- 这只狗出现了严重的肺炎,肺胸炎和全身感染迹象.
- 培养和组织病理学证实了Burkholderia pseudomallei作为有机粉症的致病原体.
- 手术干预 (腹腔切除术) 与长期抗菌药物治疗相结合,导致临床康复.
- 患者出现局部并发症 (水),后来通过继续抗生素治疗而得到缓解.
- 在长期随访期间,没有观察到有机症的复发.
结论:
- 这一案例证明了通过手术切除和适当的抗微生物药物治疗的结合来成功治疗犬肺结核病.
- 它扩大了已知的犬肉结核病的地理分布,并强调了环境因素 (如洪水) 在疾病传播中的潜在作用.
- 早期识别,积极的治疗和长期监测对于在犬性粉症中取得良好的结果至关重要.
相关概念视频
02:17Ecological Succession
21.6K
Ecological succession is influenced by the processes of facilitation, inhibition, and toleration. Facilitation occurs when early successional species create more favorable ecological conditions for subsequent species, such as enhanced nutrient, water, or light availability. In contrast, inhibition happens when early successional species create unfavorable ecological conditions for potential successive species, such as limiting resource availability. In some cases, later successional species...
21.6K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
621
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
621
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
484
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
484
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
524
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
524
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
634
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
634
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
559
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
559